Mandate

Vinge advises Nuevolution in connection with its listing on Nasdaq Stockholm

Vinge advises Nuevolution AB (publ) in connection with its list change from Nasdaq First North Premier to Nasdaq Stockholm’s main market.

The prospectus was published on 20 June 2018 and the trading on Nasdaq Stockholm commenced on 25 June 2018.
 
Nuevolution AB (publ) is a small molecule drug discovery biotech company. The company was founded in 2001 and is headquartered in Copenhagen, Denmark. 
 
Vinge’s team has primarily consisted of Dain Hård Nevonen, David Andersson, Maria Schultzberg, Nils Fredrik Dehlin, Malte Hedlund, Anna Thoms, Klara Secher and Victor Ericsson.

Related

Vinge advises Karl Hedin and the minority owners in connection with the sale of AS Toftan to Combiwood

Vinge has advised Karl Hedin and the minority owners in connection with the sale of AS Toftan to Combiwood Grupp OÜ (“Combiwood”).
May 22, 2025

Vinge has advised the FEA Group, which includes Freys Hyrverk and Stockholm Limousine Service, in connection with its merger with Inclusion Services International

The merger strengthens the new FEA Group’s capacity and service offering, which includes everything from comprehensive travel planning and hotel bookings to security-classified passenger transport and risk assessments. According to management, the newly formed group will have a unique position in the Swedish market with the opportunity to introduce new transport and security solutions that are currently unmatched in the country.
May 21, 2025

Vinge advises EHF Invest on its public offer for Real Fastigheter

EHF Invest AB has made a public offer for all shares in Real Fastigheter AB (publ).
May 21, 2025